- Home
- UFCS vs OCS Comparison
UFCS vs OCS Comparison
Compare UFCS & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- OCS
- Stock Information
- Founded
- UFCS 1946
- OCS 2003
- Country
- UFCS United States
- OCS Switzerland
- Employees
- UFCS N/A
- OCS N/A
- Industry
- UFCS Property-Casualty Insurers
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- OCS Health Care
- Exchange
- UFCS Nasdaq
- OCS Nasdaq
- Market Cap
- UFCS 666.1M
- OCS 689.8M
- IPO Year
- UFCS N/A
- OCS N/A
- Fundamental
- Price
- UFCS $27.76
- OCS $17.89
- Analyst Decision
- UFCS Buy
- OCS Strong Buy
- Analyst Count
- UFCS 2
- OCS 4
- Target Price
- UFCS $30.00
- OCS $30.25
- AVG Volume (30 Days)
- UFCS 103.5K
- OCS 45.4K
- Earning Date
- UFCS 05-06-2025
- OCS 05-07-2025
- Dividend Yield
- UFCS 2.26%
- OCS N/A
- EPS Growth
- UFCS N/A
- OCS N/A
- EPS
- UFCS 2.39
- OCS N/A
- Revenue
- UFCS $1,253,307,000.00
- OCS $757,024.00
- Revenue This Year
- UFCS $13.54
- OCS $57.00
- Revenue Next Year
- UFCS $9.84
- OCS $1,820.89
- P/E Ratio
- UFCS $11.49
- OCS N/A
- Revenue Growth
- UFCS 14.41
- OCS N/A
- 52 Week Low
- UFCS $18.04
- OCS $10.79
- 52 Week High
- UFCS $31.70
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- UFCS 52.19
- OCS 49.48
- Support Level
- UFCS $26.27
- OCS $17.54
- Resistance Level
- UFCS $27.48
- OCS $18.55
- Average True Range (ATR)
- UFCS 1.26
- OCS 0.85
- MACD
- UFCS 0.02
- OCS 0.24
- Stochastic Oscillator
- UFCS 59.65
- OCS 85.49
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.